← Back
Data updated: Mar 10, 2026
DEXCEL
Infectious DiseaseCardiovascularGastroenterology
DEXCEL is a specialty pharmaceutical company focused on Infectious Disease, Cardiovascular, Gastroenterology. Key products include ESOMEPRAZOLE MAGNESIUM.
2000
Since
12
Drugs
-
Trials
224
Approved (2yr)
Recent Activity
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
VENLAFAXINE HYDROCHLORIDE 2026-01-30
Labeling
DICLOFENAC SODIUM 2025-12-31
Labeling
TOFACITINIB CITRATE 2025-11-17
DICLOFENAC SODIUM 2025-11-05
PANTOPRAZOLE SODIUM 2025-10-15
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 25%
2 drugs
Cardiovascular 25%
2 drugs
Gastroenterology 25%
2 drugs
Oncology 13%
1 drugs
Neurology 13%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Infectious Disease, Neurology
Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Oncology
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular
Novo Nordisk big-pharma
Oncology, Cardiovascular, Infectious Disease, Neurology
Active (8)
Discontinued (4)
Company Info
- First Approval
- 2000-04-17
- Latest
- 2025-07-14
- Applications
- 14
FDA Sponsor Names
DEXCELDEXCEL LTD